FDA Approves First Oral Drug to Treat Multiple Sclerosis (MS)

On September 22, 2010, The FDA, approved Gilenya (fingolimod), the first oral drug for multiple sclerosis (MS). Gilenya is used to treat  relapsing  and remitting form of MS. The drug has been shown to significantly reduces MS attacks. However, there can be serious side effects, with possible heart, lung, and eye toxicity and increased risk of infection. Side effect can include

  • Elevated liver enzymes
  • Macular edema (swelling of the central portion of the retina, causing distorted vision)
  • Elevated blood pressure
  • Shortness of breath
  • Bronchitis
  • Diarrhea
  • Bradycardia (slowing of the heartbeat, seen only upon first treatment. The FDA panel recommended that patients be required to receive their first dose under medical supervision).

     

     

    • Posted by Gary at 9/22/2010 1:27 PM
    Categories: New MS Drug
    Tags: New Drug For Multiple Sclerosis New treatment for MS FDA Approved MS Treatments
     

    What did you think of this article?




    Trackbacks
    Trackback specific URL for this post
    • No trackbacks exist for this post.
    Comments
    Display comments as (Linear | Threaded)

    • 9/22/2010 8:38 PM Health Insurance Quotes wrote:
      Although dangerous, these side effects don't seem as extreme as many of the pharmaceuticals out there. It would be very exciting if this drug works well. It's a great step toward finding a cure.

      Candace
      Reply to this
      1. 9/22/2010 10:41 PM Howard wrote:
        I agree, all drugs have some side effects,sometimes you have to way risk VS gain. The current(approved) treatments all have side effects. We will be able to measure the success of this drug in years to come. For now we can only hope that we have a safer more effective treatment.
        Reply to this
    Leave a comment

    Submitted comments are subject to moderation before being displayed.

     Enter the above security code (required)

     Name

     Email (will not be published)

     Website

    Your comment is 0 characters limited to 3000 characters.